The efficacy and toxicity of VAD in the treatment of myeloma and related disorders.
Impressive results have recently been reported in 29 cases of advanced refractory myeloma treated with 4-d infusions of Vincristine and Adriamycin (VAD). We report our own experience with this protocol in 13 cases of myeloma and related lymphoproliferative disorders. In 2 of these cases, VAD was used as first line treatment. Objective responses were seen in two-thirds of cases and the major complication of therapy was infection, predominantly bacterial in nature.
D000971:Antineoplastic Combined Chemotherapy Protocols; D001424:Bacterial Infections / Q000139:chemically induced; D003907:Dexamethasone; D004317:Doxorubicin / Q000009:adverse effects / Q000627:therapeutic use; D004341:Drug Evaluation; D006801:Humans; D008232:Lymphoproliferative Disorders / Q000188:drug therapy*; D009101:Multiple Myeloma / Q000188:drug therapy*; D014750:Vincristine / Q000009:adverse effects / Q000627:therapeutic use
D014750:Vincristine; D003907:Dexamethasone; D004317:Doxorubicin